Product Packing: 10X10
Product Composition: pantoprazole 40 mg + Domperidone 30 mg SR
Product Price: MRP : 1130
RPNIP DSR Capsules contain Rabeprazole Sodium
20 mg and Domperidone 30 mg in a sustained-release formulation. This
prescription combination is used in the management of acid-related
gastrointestinal disorders, particularly when symptoms of gastroesophageal
reflux are associated with nausea, vomiting, bloating, or delayed gastric
emptying.
Rabeprazole
is a proton pump inhibitor (PPI) that reduces gastric acid secretion,
while Domperidone is a prokinetic and antiemetic medicine that helps improve
upper gastrointestinal motility. Together, they provide complementary support
for controlling reflux-related symptoms and associated gastric discomfort.
Each capsule contains:
·
Rabeprazole
Sodium – 20 mg
·
Domperidone
– 30 mg (Sustained Release)
·
Capsule
dosage form
·
Pack
Size – 10 x 10 Capsules
·
For
oral use
RPNIP
DSR may be prescribed by a healthcare professional for conditions such as:
·
Gastroesophageal
reflux disease (GERD)
·
Acid
reflux and heartburn
·
Acid-related
dyspepsia
·
Nausea
and vomiting associated with gastric disorders
·
Bloating
and upper abdominal discomfort
·
Delayed
gastric emptying or reflux-associated fullness
·
Other
acid-peptic conditions where combined acid suppression and prokinetic therapy
is considered appropriate
The
combination is intended for patients who require both suppression of excessive
gastric acid and improvement of gastrointestinal motility. The exact indication
and duration of therapy should always be determined by a qualified healthcare
professional.
RPNIP DSR works
through the complementary actions of Rabeprazole and Domperidone:
Rabeprazole: A proton pump inhibitor that blocks the final step of
gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric
parietal cells. This helps reduce stomach acidity and relieve acid-related
symptoms.
Domperidone: A dopamine D2-receptor
antagonist with prokinetic and antiemetic activity. It can enhance
gastrointestinal motility and help reduce nausea, vomiting, bloating, and
reflux-associated fullness in appropriately selected patients.
Sustained-Release Domperidone: The sustained-release
component is designed to provide prolonged release of Domperidone over time,
according to the product formulation.
Together, these actions help control
acid secretion while supporting gastric motility, providing combined symptom
management in suitable patients.
Dosage and Direction for Use
It is commonly administered before
food when prescribed, and the capsule should be swallowed whole with water
unless otherwise directed by the physician.
Do not crush, chew, open, or exceed
the prescribed dose. Do not continue treatment longer than advised without
medical review.
Possible Side Effects
·
Headache or dizziness
·
Dry mouth
·
Nausea or abdominal discomfort
·
Diarrhoea or constipation
·
Flatulence
·
Rarely, allergic reactions, changes in heart rhythm, or other serious
adverse effects may occur
If severe, unusual, or persistent symptoms occur, or if
palpitations, fainting, or allergic symptoms develop, seek medical attention
promptly.
Before using RPNIP DSR, the following precautions should be
considered:
·
Use only under medical supervision and according to the prescribed dose
and duration.
·
Inform the physician about heart rhythm disorders, significant liver
disease, electrolyte disturbances, or other major medical conditions.
·
Domperidone may not be suitable for some patients with cardiac
conditions or those taking medicines that can affect heart rhythm or interact
with its metabolism.
·
Pregnant or breastfeeding women should use this medicine only if
specifically advised by a healthcare professional.
·
Inform the physician about all prescription medicines, over-the-counter
medicines, and supplements being taken.
·
Keep out of reach of children.
·
Store in a cool, dry place away from direct sunlight and moisture, as
directed on the product pack.
RPNIP DSR offers pharmaceutical
distributors and healthcare entrepreneurs an opportunity to add a commonly
prescribed gastroenterology combination to their product portfolio.
Acid-peptic disorders,
reflux symptoms, and related gastrointestinal complaints are frequently
encountered in clinical practice. A Rabeprazole plus sustained-release
Domperidone combination can therefore be a relevant addition to
gastroenterology and general physician-focused product portfolios, subject to
responsible prescription-based promotion.
·
Established PPI + prokinetic combination segment
·
Relevant to gastroenterology and general physician portfolios
·
Convenient capsule dosage form
·
10 x 10 pack configuration suitable for pharmaceutical distribution
·
Potential for prescription-based promotion through appropriate
healthcare channels
·
Opportunity to strengthen the gastrointestinal product range
Ethics Medinova Private
Limited
offers PCD Pharma Franchise opportunities for RPNIP DSR in selected territories
across India, subject to availability and mutually agreed terms.
Franchise Partners can
benefit from the company’s growing product portfolio, professional promotional
support, and business assistance.
·
Monopoly-based territory opportunities, subject to availability
·
Attractive promotional materials and visual aids
·
Product information and marketing support
·
Reliable supply coordination
·
Access to a growing pharmaceutical product portfolio
·
Professional partner assistance
Partner with Ethics Medinova to
explore PCD Pharma Franchise opportunities for RPNIP DSR and other quality-focused healthcare
products.
Ethics Medinova also
provides support for businesses looking for third-party manufacturing of
Rabeprazole 20 mg + Domperidone 30 mg Sustained Release Capsules under
their own brand, subject to applicable regulatory requirements.
Our third-party
manufacturing support may include:
·
Customized product and formulation requirements
·
Private-label manufacturing opportunities
·
Customized packaging and branding support
·
Product label and pack configuration assistance
·
Manufacturing coordination through suitable facilities
·
Support for documentation and applicable regulatory requirements
This service is suitable
for pharmaceutical companies, healthcare brands, startups, and entrepreneurs
looking to develop their own branded gastroenterology products in accordance
with applicable laws and regulatory requirements.
RPNIP DSR is a prescription
combination of Rabeprazole 20 mg and Domperidone 30 mg SR. It may be prescribed
for GERD, acid reflux, heartburn, acid-related dyspepsia, and associated
symptoms such as nausea, bloating, or delayed gastric emptying when a physician
considers the combination appropriate.
Rabeprazole reduces stomach
acid by inhibiting the gastric proton pump. Domperidone acts as a prokinetic
and antiemetic medicine, helping improve upper gastrointestinal motility and
control nausea or vomiting in suitable patients.
RPNIP DSR should be taken
exactly as prescribed by a healthcare professional. It is commonly advised
before food; the capsule should generally be swallowed whole with water.
The duration of treatment
should be decided by the prescribing physician. Long-term or repeated use
should not be continued without appropriate medical review.
Possible side effects
include headache, dizziness, dry mouth, abdominal discomfort, bowel changes, or
flatulence. Rare cardiac rhythm problems may occur in susceptible patients.
Patients with cardiac
rhythm problems, significant liver disease, pregnancy or breastfeeding, or
those taking regular medicines should seek medical advice before use.
Yes. Ethics Medinova offers
PCD Pharma Franchise opportunities for selected products and territories,
subject to availability and mutually agreed business terms.
Yes. Third-party
manufacturing and private-label support may be explored for Rabeprazole 20
mg + Domperidone 30 mg SR Capsules, subject to applicable regulatory
requirements.
RPNIP DSR is a prescription medicine. Use only under qualified medical
supervision and according to the approved product label and applicable
regulations.
